The U.S. Food and Drug Administration (FDA) approved Novocure’s non-invasive NovoTTF-100A System for the treatment of brain tumors. The NovoTTF, a portable, wearable device that delivers anti-cancer therapy as patients pursue their normal daily activities, is the first ever medical device for the treatment of cancer as an alternative to chemotherapy. 

The device was approved for the treatment of patients with so-called recurrent glioblastoma, or cancer that continues to grow after treatments like surgery and chemotherapy. 

Novocure, which has a research center in Haifa, is also conducting clinical trials of the NovoTTF on newly diagnosed glioblastoma patients in addition to standard treatments as well as in non-small cell lung-cancer.

%d bloggers like this: